
|Articles|July 15, 2003
Brimonidine battle begins with B&L launch
Rochester, NY-Now that Bausch &Lomb has won its battle to release its generic version of brimonidine tartrate ophthalmic solution 0.2% (Alphagan, Allergan), the ophthalmic industry is waiting to see whether physicians will choose the generic version of the old standard or brimonidine tartrate 0.15% (Alphagan P, Allergan).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
3
AAO 2025: The evolution of eye care on display at AAO 2025
4
AAO 2025: Trial demonstrates safety and efficacy of epithelium-on cross linking
5